Navigation Links
Rigel Announces Fourth Quarter and Year End 2010 Financial Results
Date:3/1/2011

t plans on conducting an additional allergen challenge trial in 2011.

Rigel's research and development teams are currently concentrating on the following five potential new products in the pipeline:

  • JAK3 inhibitor (oral) - Rigel's oral Janus kinase 3 (JAK3) inhibitor may provide a significant solution to the problem of organ transplant rejection for the approximately 90,000 people undergoing major organ transplants each year.  Rigel expects to begin Phase 1 clinical trials with this program by the end of 2011.
  • JAK3 inhibitor (ophthalmic) - Approximately 4 million people in the U.S. have Sjogren's disease, an autoimmune disorder that affects the lacrimal glands of the eye.  Present therapies for this chronic and painful condition are only mildly effective.  Rigel has developed a soluble JAK3 inhibitor for topical ophthalmic use (eye drops) that it expects to enter into phase 1 clinical trials in 2011.
  • PKC theta inhibitor - Protein Kinase C Theta (PKC theta) is an immune system activator whose expression is limited to certain immune and muscle cells, and has been shown to be significant in the progression of multiple sclerosis (MS).  Rigel's research is focused on developing a PKC theta inhibitor that would target the inflammation of the nerve cells, characteristic of MS, thereby reducing the unpredictable and potentially devastating effects of the disease.  Rigel expects to select an oral PKC theta inhibitor product candidate in 2011.
  • ACVR2B inhibitor (Muscle Activation) - Patients with many serious diseases including diabetes, HIV, cancer and chronic heart failure are prone to develop cachexia, a disorder characterized by muscle atrophy.  The loss of muscle critical to breathing and homeostasis is frequently the cause of death in patients with these serious diseases.  In preclinical studies, Rigel's oral ACVR2B inhibitors have been shown to block the cycle of muscle degradation.  Rigel
    '/>"/>

  • SOURCE Rigel Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
    2. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
    3. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
    4. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
    5. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
    6. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
    7. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
    8. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
    9. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
    10. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
    11. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/29/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/ltwldz/surgicaloperating ... "Surgical/Operating Microscopes Market by Application & End User ... their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... to reach $806.6 million by 2020 from $402.2 ... from 2015 to 2020. , ,Major factors fueling ...
    (Date:5/29/2015)... 2015  Haemonetics Corporation (NYSE: HAE ) announced ... will present at the JMP Securities Life Sciences Conference ... 23 rd , 2015 at 11:30am Eastern time.  ... live via webcast at: http://wsw.com/webcast/jmp27/hae ... is a global healthcare company dedicated to providing innovative ...
    (Date:5/29/2015)... 29, 2015  Epic Sciences announced today that the ... metastatic castrate resistant prostate cancer patients, at the ... Clinical Oncology. This application expands the investigational utility ... platform to characterize circulating tumor cell (CTC) ... patients have heterogeneous clonal CTC populations harboring separate ...
    Breaking Medicine Technology:Surgical/Operating Microscopes Market by Application & End User - Global Forecast to 2020 for the $806 Million Industry 2Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 2Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 3
    ... PSTX) today announced that The Mount Sinai Hospital in New York City has implemented its Safety-Sponge System. , ... , , ... ... ...
    ... N.J. , March 15 Regado Biosciences, Inc., ... with active control agents, announced that Chris Rusconi , ... Zelenkofske , DO, FACC, Senior Vice President , Chief Medical ... on Monday, March 15, 2010 in Atlanta, ...
    Cached Medicine Technology:Patient Safety Technologies, Inc., Contracts to Implement the Safety-Sponge(TM) System at The Mount Sinai Hospital in New York 2Patient Safety Technologies, Inc., Contracts to Implement the Safety-Sponge(TM) System at The Mount Sinai Hospital in New York 3Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010 2Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010 3Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010 4
    (Date:5/30/2015)... Ill. (PRWEB) May 30, 2015 Twelve ... were recognized by their peers as the 2015 ... by OncLive® at the Chicago Illuminating Company last night. ... of eminent oncologists for landmark achievements in translational research, ... changed the course of cancer treatment. , Honorees were ...
    (Date:5/30/2015)... Thousands of aesthetic industry professionals converged ... by the American Society for Aesthetic Plastic Surgery (ASAPS). ... Zeltiq, the parent company of one of the fastest ... blazing growth, the one-of-a-kind device just sold its 2 ... currently in the news for gaining the FDA’s stamp ...
    (Date:5/30/2015)... May 30, 2015 On Thursday, ... Dr. Charles Simone and Dr. Evan Alley both ... ‘Meet the Mesothelioma Experts’ series. The interview was ... mesothelioma centers of excellence. Drs. Simone and Alley ... Mary Hesdorffer, with whom they discussed the mesothelioma ...
    (Date:5/30/2015)... May 30, 2015 Responding to surging ... travelers who experienced OGAWA products while abroad, OGAWA-engineered massage ... , A leader in the Asian health and ... designer, researcher, developer and manufacturer of health and wellness ... craftsmanship of their products, health enthusiasts in Asia and ...
    (Date:5/30/2015)... 30, 2015 Cyclist Barry Haarde ... for the World 2015: Piles of Miles” near ... awareness about hemophilia and encourage individuals to support ... , Save One Life supports nearly 1,200 impoverished ... countries through direct sponsorships, scholarships and micro-enterprise grants. ...
    Breaking Medicine News(10 mins):Health News:OncLive’s 2015 Giant of Cancer Care™ Awards Announced 2Health News:OncLive’s 2015 Giant of Cancer Care™ Awards Announced 3Health News:OncLive’s 2015 Giant of Cancer Care™ Awards Announced 4Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 2Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 3Health News:Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 3Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2
    ... DALLAS Feb. 3, 2011 UT Southwestern Medical ... a national network that conducts clinical trials aimed at ... 100 community treatment providers and academic medical centers throughout ... Institute on Drug Abuse,s Clinical Trials Network (CTN). The ...
    ... (HealthDay News) -- Researchers report that DNA analysis has led ... disease, along with its genetic cause. As described in ... of Medicine , the debilitating, painful and progressive disease is ... and feet of patients, and in the vascular network below ...
    ... By Kathleen Doheny HealthDay Reporter , WEDNESDAY, ... can help predict a daughter,s chances of not only having ... attack, new research shows. "Our new study shows that ... said Dr. Amitava Banerjee, a clinical research associate at the ...
    ... decades, cardiologists have searched for ways to see dangerous ... researchers at Washington University School of Medicine in St. ... clots and make them visible to a new kind ... PhD, a Washington University cardiologist at Barnes-Jewish Hospital, these ...
    ... is available in French . Montreal, February ... bisexual (LGB) are at far higher risk for severe mental ... University suggests that the stress of being rejected or victimized ... gays and bisexuals. Recently published as a doctoral ...
    ... schools closures has been considered as a means of reducing ... at the peak of an epidemic but new research led ... school closures are ineffective and that only significant widespread school ... epidemic and the strain placed on hospital intensive care units. ...
    Cached Medicine News:Health News:Researchers lead search for better drug-addiction treatments 2Health News:Scientists Discover Rare Vascular Disease 2Health News:If Mom Had a Stroke, Daughter May Be Prone to Heart Attack 2Health News:If Mom Had a Stroke, Daughter May Be Prone to Heart Attack 3Health News:New nanoparticles make blood clots visible 2Health News:New nanoparticles make blood clots visible 3Health News:Physiological impacts of homophobia 2Health News:Physiological impacts of homophobia 3Health News:Widespread school closures needed to stop strain on hospitals during epidemics 2
    Used for emergency airway access when conventional endotracheal intubation cannot be performed....
    ... Standard/Conventional. Stainless steel. Lamp supplied with ... high quality standard incandescent laryngoscope blades. The ... refined through many years of use the ... are manufactured to exacting specifications from the ...
    ... Standard/Conventional Blade. Stainless Steel. Lamp supplied ... tradition of high quality standard incandescent ... blades have been continually refined through ... over to minimize maintenance requirements. They ...
    ... Rusch Snap-Light™ laryngoscope blades are designed ... diameter fiber optic bundle can be removed ... hard to reach areas. Our unique snap-on ... The bright focused blades are interchangeable with ...
    Medicine Products: